Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 14/20 | 0.62 |
| ▸ | AKT1 | P31749 | 6/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.62 |
| ▸ | JAK3 | P52333 | 4/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 2/20 | 0.50 |
| ▸ | JAK1 | P23458 | 2/20 | 0.50 |
| ▸ | TYK2 | P29597 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13343970 | 0.87 | AKT2 (0.81) | AKT2AKT1CYP2C9ROCK2KCNH2 | |
| SCHEMBL3491469 | 0.86 | AKT2 (0.64) | AKT2AKT1CYP2C9ROCK2KCNH2 | |
| SCHEMBL13510875 | 0.79 | KIT (0.64) | AKT2AKT1CYP2C9ROCK2KCNH2 | |
| SCHEMBL2778397 | 0.79 | JAK3 (0.63) | AKT2AKT1ROCK2AKT3JAK3 | |
| SCHEMBL13343949 | 0.78 | NAMPT (0.44) | CYP2C9 | |
| SCHEMBL3491932 | 0.77 | NAMPT (0.43) | CYP2C9 | |
| SCHEMBL1001031 | 0.77 | AKT2 (1.00) | AKT2AKT1CYP2C9ROCK2KCNH2 | |
| SCHEMBL13510881 | 0.76 | AKT2 (0.78) | AKT2AKT1CYP2C9ROCK2KCNH2 | |
| SCHEMBL13512945 | 0.76 | JAK3 (0.63) | AKT2AKT1CYP2C9ROCK2KCNH2 | |
| Hydrochloric Acid SCHEMBL2782341 | 0.76 | AKT2 (0.76) | AKT2AKT1CYP2C9ROCK2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| WO-2008075110-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | GRK2, GNAO1, PTGER1 | AKT2 27/4885AKT1 40/4885CYP2C9 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.